Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 173

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 173
---
 popularity globally.                                    |

| ● | Zepbound                                                                                  
 (tripeptide): Approved by the FDA in late 2023, Zepbound offers even greater efficacy. A  
 dual GIP and GLP-1 agonist, it showed a 22.5% average body weight reduction in late-stage 
 trials, surpassing all previous medications.                                              |

Liraglutide (Saxenda)

An earlier GLP-1 analog, Saxenda requires daily injections and yields average weight loss of 5–10%. While less effective than newer options, it remains a widely prescribed option, especially for those who may not tolerate more potent agents.

Other Approved Medications

| ● | Orlistat                                                                                  
 (Alli, Xenical): A lipase inhibitor that prevents fat absorption in the intestine. It’s   
 over the counter in many markets but often associated with gastrointestinal side effects. |

| ● | Phentermine/Topiramate                                                   
 (Qsymia): A combination drug that reduces appetite and enhances satiety. |

| ● | Naltrexone/Bupropion                                                                     
 (Contrave): A combination affecting central nervous system pathways involved in appetite 
 regulation.                                                                              |

Cost Overview

| ● | Wegovy:                                      
 Approx. $1,300 to $1,500/month (U.S. market) |

| ● | Zepbound:            
 Approx. $1,060/month |

| ● | Saxenda:             
 Approx. $1,300/month |

| ● | Orlistat:                      
 ~$50–$100/month (OTC versions) |

| ● | Qsymia                                                                            
 and Contrave: Range between $150–$300/month, depending on insurance and discounts |

| Moore Financial Consulting |

| SKNY Pharmaceuticals, Inc. | April 2025    |
| Valuation                  | Page 13 of 25 |

Prices vary widely by region and are significantly impacted by insurance coverage, generics availability, and regulatory policies.

Surgical Interventions

For individuals with severe obesity (typically BMI ≥40, or ≥35 with comorbidities), bariatric surgery remains the most effective long-term treatment. Procedures such as gastric bypass, sleeve gastrectomy, and adjustable gastric banding alter the digestive system to limit food intake and/or nutrient absorption.

Bariatric surgery can lead to 30–40% weight loss and often results in the remission of obesity-related conditions like type 2 diabetes. However, it carries risks of surgical complications